GlassScriptPhysician profile
Ijaz Ahmad
NPI 1861538712
$5,234.53
in general payments reported to CMS, 2019-2025
27 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $249 · 2021: $891 · 2022: $1,158 · 2023: $949 · 2024: $505 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $34.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.89 |
| Education | $34.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,072.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Mylan Specialty L.P. | $752.97 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $585.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $456.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $406.83 | 2019-2023 | Verquvo |
| Pfizer INC. | $283.32 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $244.25 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.15 | 2022-2023 | |
| Allergan, INC. | $197.84 | 2019 | |
| Novo Nordisk INC | $195.39 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $185.03 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $124.55 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $102.34 | 2022-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $63.82 | 2023-2024 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.89 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.54 | 2023-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $33.13 | 2019-2020 | |
| Amgen INC. | $27.54 | 2024 | Repatha |
| Viatris Specialty LLC | $24.92 | 2025 | Yupelri |
| Genentech USA, INC. | $24.28 | 2023 | Xolair |
| Organon LLC | $23.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $22.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.68 | 2022 | |
| Seqirus USA INC | $19.69 | 2022 | |
| Abbott Laboratories | $19.53 | 2021 | |
| Hikma Pharmaceuticals USA | $18.02 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ijaz Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.